| abstract |
The present invention provides novel heteroaryl compounds of formula (Ia) that are selective inhibitors of the human P2Y 1 receptor. The present invention also provides various pharmaceutical compositions thereof and methods of treating diseases responsive to modulation of P2Y 1 receptor activity. Ring A is a 5- to 6-membered heteroaryl containing carbon atoms and 1 to 4 ring heteroatoms selected from N, NR 11 , S (O) p , and O, where heteroaryl is 0 Substituted with ~ 4 R 1 ; ring B is phenyl substituted with 0-4 R 7 , pyridyl substituted with 0-3 R 7 , or 0-2 Thienyl substituted with R 7 ; X is NH or NMe; Y is O or S; R 5 is substituted with 1 to 4 R 5a — (CR f R f ) nC 3 -10 carbon ring or a carbon atom and n,, NR 11, O, and containing from 1 to 4 heteroatoms selected from S (O) p - (CR f R f) n-5 to 10-membered heterocyclic a ring, wherein the heterocyclic ring is substituted with 0-4 R5 a; other substituents and variables are defined in the claims, (Ia) or stereoisomers, tautomeric Sexually, pharmaceutically acceptable salt or solution Hydrate. |